TET2 and hematopoietic and lymphoid cell neoplasm: TET2 is frequently mutated in the majority of hematologic cancers, with a frequency of 17–37% in myeloid and 15–33% in T-cell lymphoid malignancies [46], and the disruption of its PPIs by mutations can be an important mechanism of its pathological role in these cases.